)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Mesoblast
Mesoblast (MSB) investor relations material
Mesoblast Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Apr, 2026
Executive summary
Ryoncil® net revenues reached US$30.3M for the quarter, with gross sales of US$35.3M, driven by strong February and March sales.
Net operating cash spend improved to US$4.1M, supported by US$34.6M in receipts and disciplined expense management.
Patient recruitment target achieved in pivotal phase 3 trial for chronic low back pain.
FDA cleared label extension trial for Ryoncil® in adults with SR-aGvHD and granted IND clearance for a registrational trial in Duchenne's muscular dystrophy.
Acquired exclusive license to CAR technology platform for precision-enhanced cell therapy products.
Financial highlights
Ryoncil® revenues for the first year since launch are approaching US$100M.
Cash and cash equivalents at quarter end were US$121.8M.
Payments to related parties totaled US$705K for the quarter.
Estimated quarters of funding available is 41.8, based on current cash and financing facilities.
Outlook and guidance
Commercial strategies are in place for continued revenue growth, with focus on label extensions and new indications.
Near- and mid-term blockbuster opportunities identified in inflammatory back pain and heart failure.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mesoblast
- FDA approval and new capital position the company for commercialization and growth.MSB
Registration filing23 Apr 2026 - Resale of 2,000,000 shares (200,000 ADSs) by a major shareholder, with no proceeds to the company.MSBRegistration filing23 Apr 2026
- Biotech registers 500,000 ADSs for resale; proceeds only if warrants are exercised.MSBRegistration filing23 Apr 2026
- Shareholders may resell ADSs from a recent placement as the company advances cell therapy commercialization.MSBRegistration filing23 Apr 2026
- Resale of 200,000 ADSs by a major shareholder highlights high risk and capital needs.MSBRegistration filing23 Apr 2026
- Blockbuster cell therapy programs advance toward pivotal milestones and commercial expansion.MSBR&D Day 20269 Apr 2026
- Ryoncil/RYONCIL launch drove $49M H1 FY26 revenue, 93% margin, and strong FY26 outlook.MSBH1 20267 Apr 2026
- RyoncilⓇ net revenues rose 60% to US$30M, with strong cash reserves and expanded financing.MSBQ2 202629 Jan 2026
- RYONCIL BLA resubmitted, cash burn cut 23%, and FDA decision expected by January 2025.MSBQ4 202423 Jan 2026
Next Mesoblast earnings date
H2 202622 Oct, 2026
Mesoblast
Next Mesoblast earnings date
H2 202622 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage